As an endocrinologist who treats people with type 2, Im always excited about novel interventions that indicate significant positive outcomes
In a later study by the same group, C10 but not HB prevented seizure activity in rat hippocampal slices in two different epilepsy models
I mean, there are things to complain about, he and I, but we, the two of us, we don't have anything to complain about
Higher tirzepatide concentrations mean smaller injection volumes for the same dose

PT-141 Research# PT-141 completed the full drug development pathway: RECONNECT trials : Two Phase 3 pivotal trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores compared to placebo, with a meaningful increase in satisfying sexual events FDA approval : Approved June 21, 2019, as Vyleesi for HSDD in premenopausal women Male sexual dysfunction : Earlier trials explored PT-141 for male erectile dysfunction, though this indication was not pursued to approval Dose limitations : FDA label restricts use to no more than 8 doses per month and recommends against use in patients with uncontrolled hypertension or cardiovascular disease Post-marketing : Ongoing pharmacovigilance with established adverse event reporting The regulatory gap between MT-2 and PT-141 is the fundamental differentiator: PT-141 has undergone the rigorous efficacy and safety evaluation required for FDA approval, while MT-2 has not